Clinical Trials

310 enrolled 18 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

LymphoidOther hematologic neoplasmSarcoma

803 enrolled 4 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

371 enrolled 36 charts 4 FDA

Leukemia, Myeloid, Acute

NCT03589326 2025-11-26

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

245 enrolled 15 charts 2 FDA

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

NCT03173248 2025-11-10

AGILE

146 enrolled 11 charts 2 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT04067336 2025-11-10

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Recruiting

263 enrolled 3 FDA

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02242942 2025-11-06

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

445 enrolled 22 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03069352 2025-09-30

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

211 enrolled 30 charts 3 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT02500407 2025-09-12

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

713 enrolled 2 FDA

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01784068 2025-09-10

ENESTfreedom

215 enrolled 7 charts 2 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05918913 2025-09-05

Expanded Access Program for Revumenib

No longer available

3 FDA

Leukemia, Recurrence

NCT01698905 2025-09-02

ENESTop

163 enrolled 7 charts 2 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02475681 2025-08-27

ElevateTN

535 enrolled 19 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02993523 2025-08-19

Viale-a

443 enrolled 14 charts 3 FDA

Leukemia, Myeloid, Acute

NCT01757535 2025-07-08

QUAZAR AML-001

472 enrolled 24 charts 3 FDA

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT02719574 2025-06-26

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

336 enrolled 48 charts 2 FDA

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02074839 2025-06-08

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Phase 1 Recruiting

291 enrolled 6 FDA

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT03580655 2025-04-30

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

LymphoidMyeloidOther hematologic neoplasm

107 enrolled 2 FDA

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT04666038 2025-04-20

BRUIN CLL-321

238 enrolled 17 charts 3 FDA

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT03106779 2025-04-08

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

233 enrolled 10 charts 2 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03734016 2025-03-30

ALPINE

652 enrolled 27 charts 2 FDA

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01437787 2025-03-05

JAKARTA

289 enrolled 2 FDA

Hematologic Neoplasms

NCT03836261 2024-12-27

AMPLIFY

984 enrolled 3 FDA

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01915498 2024-10-22

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

345 enrolled 120 charts 2 FDA

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT03306264 2024-08-27

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

227 enrolled 37 charts 3 FDA

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02668653 2024-08-06

QuANTUM-First

539 enrolled 20 charts 2 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT02113982 2024-08-01

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

138 enrolled 23 charts 3 FDA

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Myeloid, Acute

NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

111 enrolled 23 charts 2 FDA

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02000427 2024-05-28

Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

45 enrolled 24 charts 2 FDA

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02081378 2024-03-18

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Phase 1 Completed

326 enrolled 2 FDA

405 enrolled 27 charts 2 FDA

Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02013167 2024-03-05

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Phase 3 Terminated

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02435849 2024-02-13

ELIANA

80 enrolled 39 charts 1 FDA

229 enrolled 17 charts 4 FDA

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04145531 2023-11-18

An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

Phase 2/3 Completed

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02005471 2023-10-17

MURANO

389 enrolled 35 charts 4 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02004522 2023-09-21

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

319 enrolled 18 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

206 enrolled 40 charts 4 FDA

CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT02561988 2023-03-17

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Phase 1 Completed

86 enrolled 2 FDA

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Recurrence, Mastocytosis, Systemic

NCT02793583 2022-07-21

UNITY-NHL

Phase 2/3 Terminated

710 enrolled 2 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

536 enrolled 24 charts 2 FDA

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01844765 2021-04-22

DIALOG

59 enrolled 33 charts 2 FDA